Clinical Trial Update: A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial investigating WX390 in combination with toripalimab for advanced gastric-type endocervical adenocarcinoma with STK11 mutations; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric-type Endocervical Adenocarcinoma

Drugs mentioned

• Toripalimab (Toripalimab)
• WX390

Snippet

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd | Conditions: Gastric Type Adenocarcinoma (GAS) With STK11 Mutation | Phase 2 | Status: RECRUITING